Systemic Inflammatory Biomarkers in Ovarian Cancer

Major gynaecological cancer surgery is a procedure with high complication rates and mortality risk due to both the patient' s old age and comorbidities and the extent of the surgery. Among such surgeries, ovarian cancer-related surgery has the highest mortality rate. Despite advances in early drug therapy and improvements in the cytotoxicity of drugs, ovarian cancer is frequently diagnosed at advanced stages, which further increases morbidity and mortality rates. Although many years have passed, the prognostic role of cytoreductive surgery on survival in ovarian cancers continues to be important. Predicting postoperative outcomes in these surgeries may reduce the length of hospital stay, need for stay in the intensive care unit, complications, and mortality. Therefore, the role of systemic inflammatory biomarkers needs to be comprehensively investigated to understand the carcinogenic mechanisms better.

For this purpose, the investigators planned to evaluate the prognostic effect of systemic inflammatory biomarkers on postoperative complications.

Inclusion criteria

• Patients older than 18 years of age

Exclusion criteria

• Patients with acute or inflammatory diseases
• Patients with hematological malignancies
• Patients with autoimmune diseases patients who underwent intraoperative hyperchemotherapy (HIPEC)